Head and Neck Neoplasms

• 

  Subject Areas on Research

  • 172G>T variant in the 5' untranslated region of DNA repair gene RAD51 reduces risk of squamous cell carcinoma of the head and neck and interacts with a P53 codon 72 variant. 
  • 18F FDG PET/CT and Head and Neck Cancer: Patient Management and Outcomes. 
  • 18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus-Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002. 
  • 18F-FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracy-Results from Multicenter ACRIN 6685 Clinical Trial. 
  • 2-Deoxy-2-[18F] Fluoro-d-Glucose PET/Computed Tomography: Therapy Response Assessment in Head and Neck Cancer. 
  • 5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck. 
  • A Clinical Study to Assess Diffuse Reflectance Spectroscopy with an Auto-Calibrated, Pressure-Sensing Optical Probe in Head and Neck Cancer. 
  • A Multi-Institutional Comparison of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameter Calculations. 
  • A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. 
  • A dose calculation method including scatter for IMRT optimization. 
  • A functional variant at miRNA-122 binding site in IL-1α 3' UTR predicts risk and HPV-positive tumours of oropharyngeal cancer. 
  • A functional variant at the miR-184 binding site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck. 
  • A functional variant at the miR-885-5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer. 
  • A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium. 
  • A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. 
  • A novel functional DEC1 promoter polymorphism -249T>C reduces risk of squamous cell carcinoma of the head and neck. 
  • A novel functional variant (-842G>C) in the PIN1 promoter contributes to decreased risk of squamous cell carcinoma of the head and neck by diminishing the promoter activity. 
  • A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. 
  • A phase I/II trial of twice daily irradiation and concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. 
  • A phase II study of piritrexim in patients with advanced squamous head and neck cancer. 
  • A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. 
  • A preliminary study of the role of modulated electron beams in intensity modulated radiotherapy, using automated beam orientation and modality selection. 
  • A prognostic volumetric threshold of gross tumor volume in head and neck cancer patients treated with radiotherapy. 
  • A prospective study of squamous head and neck carcinoma. Immunologic aberrations in patients who develop recurrent disease. 
  • A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. 
  • A sex-specific association between a 15q25 variant and upper aerodigestive tract cancers. 
  • A single nucleotide polymorphism in the alcohol dehydrogenase 7 gene (alanine to glycine substitution at amino acid 92) is associated with the risk of squamous cell carcinoma of the head and neck. 
  • A singular value decomposition linear programming (SVDLP) optimization technique for circular cone based robotic radiotherapy. 
  • A trial of outpatient chemotherapy for recurrent head and neck tumors. 
  • A variant at a potentially functional microRNA-binding site in BRIP1 was associated with risk of squamous cell carcinoma of the head and neck. 
  • A variant of the DNA repair gene XRCC3 and risk of squamous cell carcinoma of the head and neck: a case-control analysis. 
  • ACR Appropriateness Criteria(®) Aggressive Nonmelanomatous Skin Cancer of the Head and Neck. 
  • ACR Appropriateness Criteria(®) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas. 
  • ACR Appropriateness Criteria® Neck Mass-Adenopathy. 
  • ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. 
  • ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis. 
  • AJR teaching file: left neck mass evaluated by PET/CT. 
  • Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. 
  • Acceleration of dose calculations for intensity-modulated radiotherapy. 
  • Active chemotherapy for metastatic stromal cell tumor of the testis. 
  • Adaptive replanning strategies accounting for shrinkage in head and neck IMRT. 
  • Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years. 
  • Adjuvant chemotherapy after surgery and radiation for stage III and IV head and neck cancer. 
  • Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. 
  • Adjuvant radiation therapy increases disease-free survival in stage IB Merkel cell carcinoma. 
  • Advanced head and neck surgery training during the COVID-19 pandemic. 
  • Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. 
  • Algorithm and performance of a clinical IMRT beam-angle optimization system. 
  • Algorithms and functionality of an intensity modulated radiotherapy optimization system. 
  • All-Cause 30-Day Mortality After Surgical Treatment for Head and Neck Squamous Cell Carcinoma in the United States. 
  • Altered pigment epithelium-derived factor and vascular endothelial growth factor levels in lymphangioma pathogenesis and clinical recurrence. 
  • Amplification and overexpression of PPFIA1, a putative 11q13 invasion suppressor gene, in head and neck squamous cell carcinoma. 
  • An assessment of patient burdens from head and neck cancer survivorship care. 
  • An intronic poly (AT) polymorphism of the DNA repair gene XPC and risk of squamous cell carcinoma of the head and neck: a case-control study. 
  • Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. 
  • Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database. 
  • Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. 
  • Anti-EBV serologic tests for nasopharyngeal carcinoma. 
  • Apoptotic capacity and risk of squamous cell carcinoma of the head and neck. 
  • Arc-modulated radiation therapy based on linear models. 
  • Artificial neural network model of survival in patients treated with irradiation with and without concurrent chemotherapy for advanced carcinoma of the head and neck. 
  • Assessing Key Stakeholders' Knowledge, Needs, and Preferences for Head and Neck Cancer Survivorship Care Plans. 
  • Assessment of PlanIQ Feasibility DVH for head and neck treatment planning. 
  • Assessment of the sensitivity and specificity of tissue-specific-based and anatomical-based optical biomarkers for rapid detection of human head and neck squamous cell carcinoma. 
  • Association between a functional polymorphism (-1195T>C) in the IGFBP5 promoter and head and neck cancer risk. 
  • Association between a rare novel TP53 variant (rs78378222) and melanoma, squamous cell carcinoma of head and neck and lung cancer susceptibility in non-Hispanic Whites. 
  • Association between novel PLCE1 variants identified in published esophageal cancer genome-wide association studies and risk of squamous cell carcinoma of the head and neck. 
  • Association between single nucleotide polymorphisms in ERCC4 and risk of squamous cell carcinoma of the head and neck. 
  • Association between the V109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma. 
  • Association of Human Papillomavirus Status With Suicide Risk Among Patients With Head and Neck Cancer. 
  • Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. 
  • Association of marijuana smoking with oropharyngeal and oral tongue cancers: pooled analysis from the INHANCE consortium. 
  • Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck. 
  • Association of p73 G4C14-to-A4T14 polymorphism with human papillomavirus type 16 status in squamous cell carcinoma of the head and neck in non-Hispanic whites. 
  • Associations between expression levels of nucleotide excision repair proteins in lymphoblastoid cells and risk of squamous cell carcinoma of the head and neck. 
  • Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. 
  • Automated Nuclear Segmentation in Head and Neck Squamous Cell Carcinoma Pathology Reveals Relationships between Cytometric Features and ESTIMATE Stromal and Immune Scores. 
  • Automating Treatment Summary Development Using Electronic Billing Information: A Pilot Study of Survivors of Head and Neck Cancer. 
  • Basal cell carcinoma originating from a nevus sebaceus on the scalp of a 7-year-old boy. 
  • Bcl10 is not a target for frequent mutation in human carcinomas. 
  • Behavioral assessment of head and neck cancer pain. 
  • Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling. 
  • Body mass index and risk of head and neck cancer in a pooled analysis of case-control studies in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium. 
  • Brachial plexus contouring with CT and MR imaging in radiation therapy planning for head and neck cancer. 
  • CASP3 polymorphisms and risk of squamous cell carcinoma of the head and neck. 
  • CT mucosal window settings: a novel approach to evaluating early T-stage head and neck carcinoma. 
  • CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu polymorphisms are not associated with risk of squamous cell carcinoma of the head and neck. 
  • Can pretreatment computed tomography findings predict local control in T3 squamous cell carcinoma of the glottic larynx treated with radiotherapy alone? 
  • Cancer cachexia syndrome in head and neck cancer patients: Part II. Pathophysiology. 
  • Cancer cachexia syndrome in head and neck cancer patients: part I. Diagnosis, impact on quality of life and survival, and treatment. 
  • Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion. 
  • Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93). 
  • Causes of death in long-term survivors of head and neck cancer. 
  • Cerebral atrophy in an infant following treatment with ifosfamide. 
  • Cervical thymoma. 
  • Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk. 
  • Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. 
  • Challenges in Microsurgical Reconstruction for Craniofacial Osteomyelitis With Resultant Osteonecrosis. 
  • Change in stage of presentation of head and neck cancer in the United States before and after the affordable care act. 
  • Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. 
  • Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study. 
  • Chemoradiotherapy for locally advanced head and neck cancer. 
  • Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. 
  • Childhood passive smoke exposure is associated with adult head and neck cancer. 
  • Childhood rhabdomyosarcoma. Analysis of coordinated therapy and results. 
  • Chromosome instability and risk of squamous cell carcinomas of head and neck. 
  • Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. 
  • Clinical Factors Affecting Survival in Pediatric Vascular Tumors of the Head and Neck. 
  • Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. 
  • Clinical and dermoscopic features of 88 scalp naevi in 39 children. 
  • Clinical applications of PET in oncology. 
  • Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. 
  • Clinical use of transcatheter electrocoagulation. 
  • Combination chemotherapy with cytosine arabinoside (Ara-C) and cis-diamminedichloroplatinum (CDDP) for squamous cancers of the upper aerodigestive tract. 
  • Combined effects of E2F1 and E2F2 polymorphisms on risk and early onset of squamous cell carcinoma of the head and neck. 
  • Comparison of animal models for head and neck cancer cachexia. 
  • Comparison of complications in free flap reconstruction for osteoradionecrosis in patients with or without hyperbaric oxygen therapy. 
  • Comparison of the Financial Burden of Survivors of Head and Neck Cancer With Other Cancer Survivors. 
  • Comparison of two head and neck immobilization systems. 
  • Competing causes of death in the head and neck cancer population. 
  • Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies. 
  • Comprehensive population-averaged arterial input function for dynamic contrast-enhanced vmagnetic resonance imaging of head and neck cancer. 
  • Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. 
  • Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. 
  • Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53). 
  • Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. 
  • Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results. 
  • Contemporary radiotherapy in head and neck cancer: balancing chance for cure with risk for complication. 
  • Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. 
  • Coping with cancer. 
  • Correspondence re: Zheng et al, Haplotype of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study. 11: 640-645, 2002. 
  • Couple-based communication intervention for head and neck cancer: a randomized pilot trial. 
  • Current status of clinical trials in head and neck cancer 2014. 
  • Cutaneous melanoma of the head and neck. A review of 399 cases. 
  • Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. 
  • DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. 
  • DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. 
  • Decreased cancer-independent life expectancy in the head and neck cancer population. 
  • Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. 
  • Defining cancer cachexia in head and neck squamous cell carcinoma. 
  • Deformable registration of preoperative PET/CT with postoperative radiation therapy planning CT in head and neck cancer. 
  • Demographic predictors of head and neck cancer survival differ in the elderly. 
  • Dendritic cell vaccines targeting survivin in head and neck cancer. 
  • Descriptive epidemiology and risk factors for head and neck cancer. 
  • Detection of squamous cell carcinoma and corresponding biomarkers using optical spectroscopy. 
  • Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes. 
  • Development and Evaluation of a Navigation-Based, Multilevel Intervention to Improve the Delivery of Timely, Guideline-Adherent Adjuvant Therapy for Patients With Head and Neck Cancer. 
  • Development and Implementation of an Educational Simulation Workshop in Fiberoptic Laryngoscopy for Radiation Oncology Residents. 
  • Diagnostic Accuracy of Follow-Up FDG PET or PET/CT in Patients With Head and Neck Cancer After Definitive Treatment: A Systematic Review and Meta-Analysis. 
  • Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites. 
  • Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancer. 
  • Differential Outcomes Among Survivors of Head and Neck Cancer Belonging to Racial and Ethnic Minority Groups. 
  • Diffusion-weighted imaging for head and neck squamous cell carcinoma: quantifying repeatability to understand early treatment-induced change. 
  • Digital tomosynthesis with an on-board kilovoltage imaging device. 
  • Does Quitting Smoking Make a Difference Among Newly Diagnosed Head and Neck Cancer Patients? 
  • Does the number of sentinel lymph nodes removed affect the false negative rate for head and neck melanoma? 
  • Double blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancers. 
  • Duraplasty in cranial base resection. 
  • Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. 
  • Dynamic Contrast-Enhanced MR Imaging in Head and Neck Cancer: Techniques and Clinical Applications. 
  • Dynamic contrast enhanced-MRI in head and neck cancer patients: Variability of the precontrast longitudinal relaxation time (T10). 
  • Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters. 
  • Dynamic contrast-enhanced magnetic resonance imaging for head and neck cancers. 
  • EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. 
  • ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma. 
  • Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. 
  • Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. 
  • Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. 
  • Effect of distractions on operative performance and ability to multitask--a case for deliberate practice. 
  • Effect of patient setup errors on simultaneously integrated boost head and neck IMRT treatment plans. 
  • Effect of physician perspective on allocation of Medicare resources for patients with advanced cancer. 
  • Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia. 
  • Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model. 
  • Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. 
  • Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. 
  • Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. 
  • Efficacy of a Brief Tele-Cognitive Behavioral Treatment vs Attention Control for Head and Neck Cancer Survivors With Body Image Distress: A Pilot Randomized Clinical Trial. 
  • Elevated serum secretory immunoglobulin A levels in patients with head and neck carcinoma. 
  • Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. 
  • Endoscopic ultrasonography in the diagnosis and staging of neoplasms of the head and neck. 
  • Endoscopic-Assisted Radial Forearm Free Flap Harvest: A Novel Technique to Reduce Donor Site Morbidity. 
  • Enhanced, rapid occlusion of carotid and vertebral arteries using the AMPLATZER Vascular Plug II device: the Duke Cerebrovascular Center experience in 8 patients with 22 AMPLATZER Vascular Plug II devices. 
  • Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. 
  • Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. 
  • Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. 
  • Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4. 
  • Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. 
  • Esophageal lesions after total laryngectomy. 
  • Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27 countries. 
  • Estimation of immune cell content in tumor using single-cell RNA-seq reference data. 
  • Evaluating for disparities in place of death for head and neck cancer patients in the United States utilizing the CDC WONDER database. 
  • Evaluation of an artificial intelligence guided inverse planning system: clinical case study. 
  • Evaluation of the accuracy of a 3D surface imaging system for patient setup in head and neck cancer radiotherapy. 
  • Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. 
  • Expanding Indications for the Human Papillomavirus Vaccine: One Small Step for the Prevention of Head and Neck Cancer, but One Giant Leap Remains. 
  • Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma. 
  • Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. 
  • Expression of nucleotide excision repair proteins in lymphocytes as a marker of susceptibility to squamous cell carcinomas of the head and neck. 
  • Extent of neck dissection required after concurrent chemoradiation for stage IV head and neck squamous cell carcinoma. 
  • Extracapsular spread and the perineural extension of squamous cell cancer in the cervical plexus. 
  • Extranodal head and neck lymphoma. Prognosis and patterns of recurrence. 
  • F-18 FDG PET/CT imaging of a hidradenocarcinoma of head and neck. 
  • FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. 
  • FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy. 
  • FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site. 
  • FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma. 
  • FDG-PET assessment of the effect of head and neck radiotherapy on parotid gland glucose metabolism. 
  • FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0. 
  • FRA1 promotes squamous cell carcinoma growth and metastasis through distinct AKT and c-Jun dependent mechanisms. 
  • Factors Associated With Head and Neck Cancer Hospitalization Cost and Length of Stay-A National Study. 
  • Factors Associated With Hospital Length of Stay Following Fibular Free-Tissue Reconstruction of Head and Neck Defects: Assessment Using the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) Criteria. 
  • Factors associated with increased risk of suicide among survivors of head and neck cancer: A population-based analysis. 
  • Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. 
  • Factors associated with time to surgery in melanoma: An analysis of the National Cancer Database. 
  • Factors for Differential Outcome Across Cancers in Clinical Molecule-Targeted Fluorescence Imaging. 
  • Factors that impact health-related quality of life over time for individuals with head and neck cancer. 
  • Family history of cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. 
  • Fanconi's anemia in adulthood: chemoradiation-induced bone marrow failure and a novel FANCA mutation identified by targeted deep sequencing. 
  • Feasibility of clinical evaluation of individuals with increased risk for HPV-associated oropharynx cancer. 
  • Feasibility of flap reconstruction in conjunction with intraoperative radiation therapy for advanced and recurrent head and neck cancer. 
  • Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. 
  • First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors. 
  • Fitting NTCP models to SBRT dose and carotid blowout syndrome data. 
  • Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT. 
  • FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients. 
  • Free flap reconstruction of the scalp and calvaria of major neurosurgical resections in cancer patients: lessons learned closing large, difficult wounds of the dura and skull. 
  • Free jejunal interposition graft for reconstruction of the esophagus. 
  • Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. 
  • Frequent loss of KAI1 expression in squamous and lymphoid neoplasms. An immunohistochemical study of archival tissues. 
  • Frequent loss of heterozygosity on chromosome arm 18q in squamous cell carcinomas. Identification of 2 regions of loss--18q11.1-q12.3 and 18q21.1-q23. 
  • Functional repeats (TGYCC)n in the p53-inducible gene 3 (PIG3) promoter and susceptibility to squamous cell carcinoma of the head and neck. 
  • Functional single nucleotide polymorphisms of the RASSF3 gene and susceptibility to squamous cell carcinoma of the head and neck. 
  • Functional variations in the ATM gene and susceptibility to differentiated thyroid carcinoma. 
  • Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. 
  • Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck. 
  • Genetic polymorphisms in the PTPN13 gene and risk of squamous cell carcinoma of head and neck. 
  • Genetic polymorphisms of p21 and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. 
  • Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. 
  • Genetic susceptibility--molecular epidemiology of head and neck cancer. 
  • Genetic variants in CYP2B6 and HSD17B12 associated with risk of squamous cell carcinoma of the head and neck. 
  • Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck. 
  • Genetic variants in selected pre-microRNA genes and the risk of squamous cell carcinoma of the head and neck. 
  • Genetic variants of NOXA and MCL1 modify the risk of HPV16-associated squamous cell carcinoma of the head and neck. 
  • Genetic variants of a BH3-only pro-apoptotic gene, PUMA, and risk of HPV16-associated squamous cell carcinoma of the head and neck. 
  • Genetic variants of p27 and p21 as predictors for risk of second primary malignancy in patients with index squamous cell carcinoma of head and neck. 
  • Genetic variants of the p53 and p73 genes jointly increase risk of second primary malignancies in patients after index squamous cell carcinoma of the head and neck. 
  • Genetic variations in TERT-CLPTM1L genes and risk of squamous cell carcinoma of the head and neck. 
  • Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. 
  • Genotypic analysis of tumor suppressor genes PTEN/MMAC1 and p53 in head and neck squamous cell carcinomas. 
  • Geriatric Assessment as a Predictor of Tolerance, Quality of Life, and Outcomes in Older Patients With Head and Neck Cancers and Lung Cancers Receiving Radiation Therapy. 
  • Global Burden of Head and Neck Cancer: Economic Consequences, Health, and the Role of Surgery. 
  • Glutathione S-transferase polymorphisms and risk of second primary malignancy after index squamous cell carcinoma of the head and neck. 
  • Glutathione-S-transferase polymorphisms and complications of microvascular head and neck reconstruction. 
  • Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. 
  • Granulocytic sarcoma in the absence of myeloid leukemia. 
  • HPV status-independent association of alcohol and tobacco exposure or prior radiation therapy with promoter methylation of FUSSEL18, EBF3, IRX1, and SEPT9, but not SLC5A8, in head and neck squamous cell carcinomas. 
  • HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. 
  • Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study. 
  • Has the outlook improved for amifostine as a clinical radioprotector. 
  • Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade. 
  • Head and Neck Cancer Survivors: Specific Needs and Their Implications for Survivorship Care Planning. 
  • Head and Neck Cancer and PET/Computed Tomography. 
  • Head and Neck Cancers, Version 1.2015. 
  • Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Head and Neck Reconstruction: Does Surgical Specialty Affect Complication Rates? 
  • Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes. 
  • Head and neck cancer as a model for advances in imaging prognosis, early assessment, and posttherapy evaluation. 
  • Head and neck cancer research collaborations between the United States and low- and middle-income countries: 10-year publication analysis. 
  • Head and neck cancer-specific quality of life: instrument validation. 
  • Head and neck cancer. Introduction. 
  • Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies. 
  • Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. 
  • Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. 
  • Head and neck cancers. 
  • Head and neck cancers. 
  • Head and neck cancers. 
  • Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: value of FDG volumetric imaging parameters. 
  • Health impact of head and neck cancer. 
  • Health-related quality of life differences between African Americans and non-Hispanic whites with head and neck cancer. 
  • High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma. 
  • High angiogenic activity in cells isolated from cystic hygroma: role of bFGF. 
  • High incidence of HPV-associated head and neck cancers in FA deficient mice is associated with E7's induction of DNA damage through its inactivation of pocket proteins. 
  • High-risk cutaneous squamous cell carcinoma without palpable lymphadenopathy: is there a therapeutic role for elective neck dissection? 
  • Histologic pattern of invasion and epithelial-mesenchymal phenotype predict prognosis in squamous carcinoma of the head and neck. 
  • How much radiation is the chemotherapy worth in advanced head and neck cancer? 
  • How should we measure and report radiotherapy-induced xerostomia? 
  • Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage. 
  • Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: a matched pair analysis. 
  • Human papillomavirus types important in progression of inverted papilloma. 
  • Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. 
  • Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. 
  • Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? 
  • Identification of distant metastases with PET-CT in patients with suspected recurrent head and neck cancer. 
  • Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer. 
  • Identification of molecular signature of head and neck cancer stem-like cells. 
  • Image-Guided Percutaneous Gastrostomy Tube Placement is Safe in Patients Requiring Aspirin 325 mg. 
  • Image-Guided Placement of Osseointegrated Implants for Challenging Auricular, Orbital, and Rhinectomy Defects. 
  • Image-guided radiosurgery of head and neck cancers. 
  • Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management. 
  • Immunocompetent murine model of cancer cachexia for head and neck squamous cell carcinoma. 
  • Immunogenetic Determinants of Susceptibility to Head and Neck Cancer in the Million Veteran Program Cohort. 
  • Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. 
  • Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer. 
  • Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. 
  • Impact of concurrent diagnostic level CT with PET/CT on the utilization of stand-alone CT and MRI in the management of head and neck cancer patients. 
  • Impact of gender on the association between marital status and head and neck cancer outcomes. 
  • Impact of smoking and smokeless tobacco on the risk of cancer of the head and neck. 
  • Impact of treatment modality on quality of life of head and neck cancer patients: Findings from an academic medical institution. 
  • In vitro BPDE-induced DNA adducts in peripheral lymphocytes as a risk factor for squamous cell carcinoma of the head and neck. 
  • In vitro benzo[a]pyrene diol epoxide-induced DNA adducts and risk of squamous cell carcinoma of head and neck. 
  • In vitro benzo[a]pyrene diol epoxide-induced DNA damage and chromosomal aberrations in primary lymphocytes, smoking, and risk of squamous cell carcinoma of the head and neck. 
  • Inactivation of the tumor suppressor genes causing the hereditary syndromes predisposing to head and neck cancer via promoter hypermethylation in sporadic head and neck cancers. 
  • Incidence and Risk of Second Primary Malignant Neoplasm After a First Head and Neck Squamous Cell Carcinoma. 
  • Incidence and Risk of Suicide Among Patients With Head and Neck Cancer in Rural, Urban, and Metropolitan Areas. 
  • Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers. 
  • Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. 
  • Incidence and risk factors of significant carotid artery stenosis in asymptomatic survivors of head and neck cancer after radiotherapy. 
  • Incorporating Multiple Perspectives Into the Development of an Electronic Survivorship Platform for Head and Neck Cancer. 
  • Incorporating single-side sparing in models for predicting parotid dose sparing in head and neck IMRT. 
  • Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group. 
  • Indocyanine green fluorescence imaging with lymphoscintigraphy for sentinel node biopsy in head and neck melanoma. 
  • Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. 
  • Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck. 
  • Induction chemotherapy: to use or not to use? That is the question. 
  • Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. 
  • Inhibition of the Continuum of Radiation-Induced Normal Tissue Injury by a Redox-Active Mn Porphyrin. 
  • Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma. 
  • Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma. 
  • Insufficient Evidence to Support or Refute the Association between Head and Neck Cancer and Marijuana Use. 
  • Insurance status, stage of presentation, and survival among female patients with head and neck cancer. 
  • Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. 
  • Intensity-modulated radiotherapy optimization with gEUD-guided dose-volume objectives. 
  • Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil. 
  • Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma. 
  • Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. 
  • Interpreting ORATOR: Lessons Learned From a Randomized Comparison of Primary Surgical and Radiation Approaches for Early-Stage Oropharyngeal Cancer. 
  • Intratherapy or Posttherapy FDG PET or FDG PET/CT for Patients With Head and Neck Cancer: A Systematic Review and Meta-analysis of Prognostic Studies. 
  • Intrathoracic metastasis from an extrathoracic malignancy: a radiographic approach to patient evaluation. 
  • Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. 
  • Involuntary smoking and head and neck cancer risk: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. 
  • Ionized serum calcium levels following combined treatment for cancer of the head and neck. 
  • Is there a "July effect" for head and neck cancer surgery? 
  • Is there a role for selective neck dissection after chemoradiation for head and neck cancer? 
  • Joint effects of alcohol consumption and polymorphisms in alcohol and oxidative stress metabolism genes on risk of head and neck cancer. 
  • Juvenile fibromatosis: hormonal receptors. 
  • Juvenile malignant melanoma of the head and neck. 
  • Knowledge and Preferences of Primary Care Providers in Delivering Head and Neck Cancer Survivorship Care. 
  • Knowledge-Based Tradeoff Hyperplanes for Head and Neck Treatment Planning. 
  • Laser-Assisted Indocyanine Green Dye Angiography for Postoperative Fistulas After Salvage Laryngectomy. 
  • Lentigo maligna melanoma of the head and neck. 
  • Lessons learned reconstructing complex scalp defects using free flaps and a cranioplasty in one stage. 
  • Lethal Suicidal Acts Among Head and Neck Cancer Survivors: The Tip of a Distress Iceberg. 
  • Literacy and laryngectomy: how should one treat head and neck cancer in patients who cannot read or write? 
  • Liver function tests: inadequate screening modality for detection of liver metastasis in head and neck carcinoma. 
  • Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. 
  • Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. 
  • Low frequency of cigarette smoking and the risk of head and neck cancer in the INHANCE consortium pooled analysis. 
  • Lymphatic mapping and sentinel node analysis: current concepts and applications. 
  • M6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patient prognosis. 
  • Machine Learning for Predicting Complications in Head and Neck Microvascular Free Tissue Transfer. 
  • Malignant melanoma induces migration and invasion of adult mesenchymal stem cells. 
  • Malignant melanoma of the mucous membranes: a review of 119 cases. 
  • Malignant melanoma with a myxoid stroma: a diagnostic pitfall on fine-needle aspiration biopsy. 
  • Marijuana smoking and the risk of head and neck cancer: pooled analysis in the INHANCE consortium. 
  • Matched analysis of survival in patients with squamous cell carcinoma of the head and neck diagnosed before and after 40 years of age. 
  • Matched-pair analysis of race or ethnicity in outcomes of head and neck cancer patients receiving similar multidisciplinary care. 
  • Matched-pair analysis of survival of never smokers and ever smokers with squamous cell carcinoma of the head and neck. 
  • Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy. 
  • Measuring tumor cycling hypoxia and angiogenesis using a side-firing fiber optic probe. 
  • Medical students' knowledge of HPV, HPV vaccine, and HPV-associated head and neck cancer. 
  • Merkel cell carcinoma: identification of prognostic factors unique to tumors located in the head and neck based on analysis of SEER data. 
  • Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. 
  • Metastatic adenocarcinoma to the neck from an unknown primary source. 
  • Methylenetetrahydrofolate reductase polymorphisms and risk of squamous cell carcinoma of the head and neck: a case-control analysis. 
  • Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas. 
  • Microsurgical composite tissue transplantation: a method of immediate reconstruction of the head and neck. 
  • Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. 
  • Mitochondrial mutations are a late event in the progression of head and neck squamous cell cancer. 
  • Mitochondrial resequencing arrays detect tumor-specific mutations in salivary rinses of patients with head and neck cancer. 
  • Modeling of multiple planning target volumes for head and neck treatments in knowledge-based treatment planning. 
  • Modeling the dosimetry of organ-at-risk in head and neck IMRT planning: an intertechnique and interinstitutional study. 
  • Modern management of chylous leak following head and neck surgery: a discussion of percutaneous lymphangiography-guided cannulation and embolization of the thoracic duct. 
  • Modifying effect of mouse double minute-2 promoter variants on risk of recurrence for patients with squamous cell carcinoma of oropharynx. 
  • Molecular Imaging and Precision Medicine in Head and Neck Cancer. 
  • Molecular Imaging in the Head and Neck: Diagnosis and Therapy. 
  • Molecular biology of head and neck cancer: risks and pathways. 
  • Monte Carlo-based dosimetry of head-and-neck patients treated with SIB-IMRT. 
  • Moving from IMRT QA measurements toward independent computer calculations using control charts. 
  • Mucosal melanoma of the head and neck. 
  • Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. 
  • Multi-system verification of registrations for image-guided radiotherapy in clinical trials. 
  • Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. 
  • Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685. 
  • Multilevel Associations Between Patient- and Hospital-Level Factors and In-Hospital Mortality Among Hospitalized Patients With Head and Neck Cancer. 
  • Multimodality surgical and hyperbaric management of mandibular osteoradionecrosis. 
  • Multiple local minima in IMRT optimization based on dose-volume criteria. 
  • Mutagen sensitivity to benzo(a)pyrene diol epoxide and the risk of squamous cell carcinoma of the head and neck. 
  • Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. 
  • Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program. 
  • Myxoid liposarcoma of the supraclavicular fossa. 
  • NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. 
  • NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. 
  • NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells. 
  • Nasal Cavity Squamous Cell Carcinoma: Factors Associated With Treatment Outcomes and Potential Organ Preservation. 
  • Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. 
  • Neck masses: illustration of a logical approach. 
  • Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer. 
  • Neighborhood deprivation and clinical outcomes among head and neck cancer patients. 
  • Ninety-day mortality following transoral robotic surgery or radiation at Commission on Cancer-accredited facilities. 
  • No Association between hOGG1 Ser326Cys polymorphism and risk of squamous cell carcinoma of the head and neck. 
  • No evidence of sex-related survival disparities among head and neck cancer patients receiving similar multidisciplinary care: a matched-pair analysis. 
  • Normal sonographic appearance of the fetal neck late in the first trimester: the pseudomembrane. 
  • Novel Manganese-Porphyrin Superoxide Dismutase-Mimetic Widens the Therapeutic Margin in a Preclinical Head and Neck Cancer Model. 
  • Novel integrative methods for gene discovery associated with head and neck squamous cell carcinoma development. 
  • Nucleotide excision repair core gene polymorphisms and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. 
  • Ocular and Periocular Tumors in Xeroderma Pigmentosum: A Study of 120 Asian Indian Patients. 
  • On the sensitivity of TG-119 and IROC credentialing to TPS commissioning errors. 
  • On the sensitivity of TG-119 and IROC credentialing to TPS commissioning errors. 
  • On-board patient positioning for head-and-neck IMRT: comparing digital tomosynthesis to kilovoltage radiography and cone-beam computed tomography. 
  • Oncologic effectiveness of selective neck dissection in the N0 irradiated neck. 
  • Opioid Abuse and Dependence in Those Hospitalized Due to Head and Neck Cancer. 
  • Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose. 
  • Organ and function preservation: the role of surgery as the optimal primary modality or as salvage after chemoradiation failure. 
  • Oropharyngeal Contamination Predisposes to Complications after Neck Dissection: An Analysis of 9462 Patients. 
  • Osteogenic sarcoma of the head and neck. The UCLA experience. 
  • Otolaryngology-head and neck surgery at Johns Hopkins: The first 100 years (1914-2014). 
  • Oxygen and Perfusion Kinetics in Response to Fractionated Radiation Therapy in FaDu Head and Neck Cancer Xenografts Are Related to Treatment Outcome. 
  • P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. 
  • PDGF-AA mediates mesenchymal stromal cell chemotaxis to the head and neck squamous cell carcinoma tumor microenvironment. 
  • PET Imaging for Head and Neck Cancers. 
  • PET Imaging of Oral Cavity and Oropharyngeal Cancers. 
  • PET/CT of cancer patients: part 2, deformable registration imaging before and after chemotherapy for radiation treatment planning in head and neck cancer. 
  • PET/Computed Tomography: Laryngeal and Hypopharyngeal Cancers. 
  • PET/Computed Tomography: Post-therapy Follow-up in Head and Neck Cancer. 
  • Pain in the head and neck cancer patient: changes over treatment. 
  • Palliative surgery for head and neck cancer with extensive skin involvement. 
  • Paraganglioma of the head and neck: long-term local control with radiotherapy. 
  • Parotid gland dose in intensity-modulated radiotherapy for head and neck cancer: is what you plan what you get? 
  • Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results. 
  • Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx. 
  • Patterns of care in older patients with squamous cell carcinoma of the head and neck: a surveillance, epidemiology, and end results-medicare analysis. 
  • Pectoralis major myocutaneous flap vs revascularized free tissue transfer: complications, gastrostomy tube dependence, and hospitalization. 
  • Pediatric radiology case of the day. Congenital goiter secondary to inherited thyroid dyshormonogenesis. 
  • Performance evaluation of automatic anatomy segmentation algorithm on repeat or four-dimensional computed tomography images using deformable image registration method. 
  • Perineural spread of melanoma demonstrated by F-18 FDG PET With MRI and pathologic correlation. 
  • Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma. 
  • Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma. 
  • Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98). 
  • Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. 
  • Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. 
  • Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. 
  • Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. 
  • Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. 
  • Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. 
  • Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. 
  • Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. 
  • Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. 
  • Planned early neck dissection before radiation for persistent neck nodes after induction chemotherapy. 
  • Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. 
  • Polymorphic hCHK2/hCds1 codon 84 allele and risk of squamous cell carcinoma of the head and neck--a case-control analysis. 
  • Polymorphisms and haplotypes of serine hydroxymethyltransferase and risk of squamous cell carcinoma of the head and neck: a case-control analysis. 
  • Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. 
  • Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. 
  • Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck. 
  • Polymorphisms of XPG/ERCC5 and risk of squamous cell carcinoma of the head and neck. 
  • Polymorphisms of methionine synthase and methionine synthase reductase and risk of squamous cell carcinoma of the head and neck: a case-control analysis. 
  • Polymorphisms of the DNA repair gene MGMT and risk and progression of head and neck cancer. 
  • Polymorphisms of the DNMT3B gene and risk of squamous cell carcinoma of the head and neck: a case-control study. 
  • Polymorphisms of vitamin D receptor gene protect against the risk of head and neck cancer. 
  • Pooled analysis of alcohol dehydrogenase genotypes and head and neck cancer: a HuGE review. 
  • Post-operative smoking status in lung and head and neck cancer patients: association with depressive symptomatology, pain, and fatigue. 
  • Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning. 
  • Potential of intensity-modulated radiotherapy to escalate doses to head-and-neck cancers: what is the maximal dose? 
  • Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck. 
  • Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. 
  • Pre-miRNA variants as predictors of clinical outcome in patients with squamous cell carcinomas of the nonoropharynx. 
  • Predictive and prognostic role of functional imaging of head and neck squamous cell carcinomas. 
  • Predictors of competing mortality in advanced head and neck cancer. 
  • Predictors of smoking relapse in patients with thoracic cancer or head and neck cancer. 
  • Predictors of stage at presentation and outcomes of head and neck cancers in a university hospital setting. 
  • Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer. 
  • Preoperative magnetic resonance angiography in fibular-free flap reconstruction of head and neck defects. 
  • Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). 
  • Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. 
  • Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. 
  • Prevalence and sociodemographic factors associated with depression among hospitalized patients with head and neck cancer-Results from a national study. 
  • Prevalence of nodal metastases in the submuscular recess (level IIb) during selective neck dissection. 
  • Primary Cancer vs Competing Causes of Death in Survivors of Head and Neck Cancer. 
  • Primary cutaneous lymphoma of the head and neck. 
  • Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. 
  • Process control analysis of IMRT QA: implications for clinical trials. 
  • Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha. 
  • Prognostic factors for fibromatoses: a correlation of proliferation index, estrogen receptor, p53, retinoblastoma, and src gene products and clinical features with outcome. 
  • Prognostic factors in head and neck melanoma. Effect of lesion location. 
  • Prognostic indicators for survival in head and neck squamous cell carcinomas: analysis of a series of 621 cases. 
  • Prognostic significance of surgical margins after transoral laser microsurgery for early-stage glottic squamous cell carcinoma. 
  • Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma. 
  • Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. 
  • Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. 
  • Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. 
  • Quantifying the Dynamics of Field Cancerization in Tobacco-Related Head and Neck Cancer: A Multiscale Modeling Approach. 
  • Quantitative Approach to Failure Mode and Effect Analysis for Linear Accelerator Quality Assurance. 
  • Quantitative optical spectroscopy can identify long-term local tumor control in irradiated murine head and neck xenografts. 
  • Racial and socioeconomic disparities associated with 90-day mortality among patients with head and neck cancer in the United States. 
  • Radiation Therapy Oncology Group. Research Plan 2002-2006. Cancer Prevention and Control Committee. 
  • Radiation and Second Primary Thyroid Cancer Following Index Head and Neck Cancer. 
  • Radiation-Associated Sarcoma of the Head and Neck: Incidence, Latency, and Survival. 
  • Radical radiotherapy for T4 carcinoma of the skin of the head and neck: a multivariate analysis. 
  • Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. 
  • Radiologic imaging of AIDS. 
  • Radionuclide lymphoscintigraphy with technetium 99m antimony sulfide colloid to identify lymphatic drainage of cutaneous melanoma at ambiguous sites in the head and neck and trunk. 
  • Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma. 
  • Randomized trial of hyperthermia and radiation for superficial tumors. 
  • Rapamycin for chemoprevention of upper aerodigestive tract cancers. 
  • Rapid Nanophotonics Assay for Head and Neck Cancer Diagnosis. 
  • Rapid determination of oxygen saturation and vascularity for cancer detection. 
  • Re: Researchers make slow headway in managing dry mouth. 
  • Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials. 
  • Reconstruction with vascularized composite tissue in patients with excessive injury following surgery and irradiation. 
  • Recurrence rates after selective neck dissection in the N0 irradiated neck. 
  • Reduced DNA double-strand break repair capacity and risk of squamous cell carcinoma of the head and neck--A case-control study. 
  • Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts contributes to risk of head and neck cancer but not tumor characteristics. 
  • Reduced DNA repair capacity in head and neck cancer patients. 
  • Reduced expression of hMLH1 and hGTBP/hMSH6: a risk factor for head and neck cancer. 
  • Reduced mRNA expression of nucleotide excision repair genes in lymphocytes and risk of squamous cell carcinoma of the head and neck. 
  • Reducing dose calculation time for accurate iterative IMRT planning. 
  • Refractory myasthenia gravis exacerbation triggered By pembrolizumab. 
  • Reirradiation for recurrent head and neck cancer. 
  • Repeatability of hypoxia PET imaging using [¹⁸F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial. 
  • Reply: Qualitative 18F-FDG PET/CT response evaluation after chemotherapy or radiotherapy for head and neck squamous cell carcinoma: is there an equivocal group? 
  • Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. 
  • Rhabdomyosarcoma of the parapharyngeal space in an adult patient: an immunohistochemical study. 
  • Rising incidence of late-stage head and neck cancer in the United States. 
  • Risk and incidence of head and neck cancers in veterans living with HIV and matched HIV-negative veterans. 
  • Risk factors for head and neck cancer in young adults: a pooled analysis in the INHANCE consortium. 
  • Risk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiation. 
  • Role for postoperative radiation therapy in adenoid cystic carcinoma of the head and neck. 
  • Role of Non-FDG-PET/CT in Head and Neck Cancer. 
  • Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. 
  • Scientific considerations for evaluating cancer bioassays conducted by the Ramazzini Institute. 
  • Scratching the Surface of Suicide in Head and Neck Cancer. 
  • Screening for cancers of the head and neck: addressing the problem. 
  • Second malignant neoplasms of the head and neck in survivors of retinoblastoma. 
  • Selective neck dissection for the treatment of neck metastasis from squamous cell carcinoma of the head and neck. 
  • Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies. 
  • Semiautomated head-and-neck IMRT planning using dose warping and scaling to robustly adapt plans in a knowledge database containing potentially suboptimal plans. 
  • Sentinel node biopsy for head and neck melanoma: a systematic review. 
  • Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells. 
  • Serum cotinine concentration and wound complications in head and neck reconstruction. 
  • Sexual behavior, HPV knowledge, and association with head and neck cancer among a high-risk group. 
  • Shared heritability and functional enrichment across six solid cancers. 
  • Significance of microRNA-related variants in susceptibility to recurrence of oropharyngeal cancer patients after definitive radiotherapy. 
  • Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas. I: dosimetric results. 
  • Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results. 
  • Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. 
  • Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. 
  • Site disparities in apoptotic variants as predictors of risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. 
  • Smokeless Tobacco Use and the Risk of Head and Neck Cancer: Pooled Analysis of US Studies in the INHANCE Consortium. 
  • Sociodemographic Differences in Patient-Reported Pain and Pain Management of Patients With Head and Neck Cancer in a Community Oncology Setting. 
  • Sociodemographic correlates of head and neck cancer survival among patients with metastatic disease. 
  • Socioeconomic and Demographic Variation in Insurance Coverage Among Patients With Head and Neck Cancer After the Affordable Care Act. 
  • Solid tumor second primary neoplasms: who is at risk, what can we do? 
  • Spontaneous resolution of a cystic neck mass in a fetus with normal karyotype. 
  • Squamous cell carcinoma of the head and neck in never smoker-never drinkers: a descriptive epidemiologic study. 
  • State Medicaid expansion status, insurance coverage and stage at diagnosis in head and neck cancer patients. 
  • Suicide risk among cancer survivors: Head and neck versus other cancers. 
  • Suicide: A Major Threat to Head and Neck Cancer Survivorship. 
  • Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. 
  • Surgery after organ preservation therapy. Analysis of wound complications. 
  • Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). 
  • Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. 
  • Survival outcomes for head and neck patients with Medicaid: A health insurance paradox. 
  • Swallowing outcomes after microvascular head and neck reconstruction: a prospective review of 191 cases. 
  • Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma. 
  • Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. 
  • TNF-α promoter polymorphisms and risk of recurrence in patients with squamous cell carcinomas of the nonoropharynx. 
  • Targeting the future in head and neck cancer. 
  • Technology evaluation: gene therapy (IL-2), Valentis Inc. 
  • Telomere length and TERT functional polymorphisms are not associated with risk of squamous cell carcinoma of the head and neck. 
  • Temporal trends in oropharyngeal cancer incidence, survival, and cancer-directed surgery among elderly Americans. 
  • Thallium-201 single-photon emission CT versus CT for the detection of recurrent squamous cell carcinoma of the head and neck. 
  • The Anterolateral Thigh Flap as the Flap of Choice for Scalp Reconstruction. 
  • The Head and Neck Survivorship Tool (HN-STAR) Trial (WF-1805CD): A protocol for a cluster-randomized, hybrid effectiveness-implementation, pragmatic trial to improve the follow-up care of head and neck cancer survivors. 
  • The Intersectionality between Race, Ethnicity, and Residential-Level Socioeconomic Status in Disparities of Head and Neck Cancer Outcomes: A SEER Study. 
  • The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC. 
  • The chemoradiation paradigm in head and neck cancer. 
  • The effect of altered Toll-like receptor 4 signaling on cancer cachexia. 
  • The effect of dental artifacts, contrast media, and experience on interobserver contouring variations in head and neck anatomy. 
  • The effect of setup uncertainty on normal tissue sparing with IMRT for head-and-neck cancer. 
  • The functional IGFBP7 promoter -418G>A polymorphism and risk of head and neck cancer. 
  • The pathology of extracranial scalp and skull masses in young children. 
  • The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. 
  • The prevention and treatment of radiotherapy - induced xerostomia. 
  • The risk of carotid stenosis in head and neck cancer patients after radiation therapy. 
  • The six-nucleotide deletion/insertion variant in the CASP8 promoter region is inversely associated with risk of squamous cell carcinoma of the head and neck. 
  • The use of hydralazine to manipulate tumour temperatures during hyperthermia. 
  • The utility of tolonium chloride rinse in the diagnosis of recurrent or second primary cancers in patients with prior upper aerodigestive tract cancer. 
  • Therapeutic and prognostic considerations of head and neck melanoma. 
  • Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features. 
  • Thin malignant melanomas of the head and neck. 
  • Three IMRT advanced planning tools: A multi-institutional side-by-side comparison. 
  • Thymidylate synthase 5'- and 3'-untranslated region polymorphisms associated with risk and progression of squamous cell carcinoma of the head and neck. 
  • Time-varying survival effects for squamous cell carcinomas at oropharyngeal and nonoropharyngeal head and neck sites in the United States, 1973-2015. 
  • Timing of percutaneous endoscopic gastrostomy tube placement in head and neck cancer patients. 
  • Total exposure and exposure rate effects for alcohol and smoking and risk of head and neck cancer: a pooled analysis of case-control studies. 
  • Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia. 
  • Traumatic hemorrhage and rapid expansion of a cervical lymphatic malformation. 
  • Treatment of head and neck cancer. 
  • Treatment recommendations for primary extradural meningiomas. 
  • Trichoblastic carcinosarcoma: A case report and literature review. 
  • Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. 
  • Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. 
  • Type of alcoholic beverage and risk of head and neck cancer--a pooled analysis within the INHANCE Consortium. 
  • Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer. 
  • Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma. 
  • Use of in situ hybridization to detect human papillomavirus in head and neck squamous cell carcinoma patients without a history of alcohol or tobacco use. 
  • Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change. 
  • Using the galactose-α-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximab. 
  • VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer. 
  • Value of magnetic resonance imaging for nodal staging in patients with head and neck squamous cell carcinoma: a meta-analysis. 
  • Vascular morphology by three-dimensional magnetic resonance imaging. 
  • Venous thromboembolism in patients with head and neck cancer after surgery. 
  • Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck. 
  • What's Love Got to do with it? Marital status and survival of head and neck cancer. 
  • Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? 
  • Whole-Slide Cytometric Feature Mapping for Distinguishing Tumor Genomic Subtypes in Head and Neck Squamous Cell Carcinoma Whole-Slide Images. 
  • XPD/ERCC2 EXON 8 Polymorphisms: rarity and lack of significance in risk of squamous cell carcinoma of the head and neck. 
  • XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. 
  • [¹⁸ F]Fluoro-DCP, a first generation PET radiotracer for monitoring protein sulfenylation in vivo. 
  • p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck. 
  • p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. 
  • p73 G4C14-to-A4T14 polymorphism and risk of second primary malignancy after index squamous cell carcinoma of head and neck. 
• 

  Keywords of People

  • Allori, Alexander C, Associate Professor of Surgery, Surgery, Plastic, Maxillofacial, and Oral Surgery
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • Esclamado, Ramon Mitra, Richard Hall Chaney, Sr. Distinguished Professor Emeritus of Otolaryngology, Head and Neck Surgery & Communication Sciences
  • Formeister, Eric John, Assistant Professor of Head and Neck Surgery & Communication Sciences, Head and Neck Surgery & Communication Sciences
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • O'Daniel, Jennifer Colleen, Assistant Professor of Radiation Oncology, Radiation Oncology
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Troy, Jesse David, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology